Pediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription database

Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross‐sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019

“…Plausible explanation for this is the increasing emergence of new oncology drugs over the past two decades 2 . In addition, the entire pediatrics field has been characterized by fewer rigorous clinical trials and subsequent off‐label prescribing worldwide including Japan compared with those for adults 3–5 . Appropriate collaboration with the industry is essential in elucidating diseases and developing treatment especially for rare diseases such as pediatric cancer.…”

“…2 In addition, the entire pediatrics field has been characterized by fewer rigorous clinical trials and subsequent off-label prescribing worldwide including Japan compared with those for adults. [3][4][5] Appropriate collaboration with the industry is essential in elucidating diseases and developing treatment especially for rare diseases such as pediatric cancer. However, unlike payments for clinical trials and research, personal payments such as lecturing reimbursement, consulting payments, and meal and beverages may undermine patient trust and influence physicians' treatment choices.…”